OR51G2

Across TCGA pan-cancer cohorts, OR51G2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR51G2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher OR51G2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR51G2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, STAD, and LUAD are the cancer types where OR51G2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
STAD	OS	Median	III,IV	0.159	0.632	.015	12	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	12	view →
SKCM	OS	Median	II,III,IV	0.353	0.740	.007	12	view →
UCEC	OS	Median	II,III,IV	1.000	0.465	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR51G2–DLBC (OS)

Open the DLBC breakdown →